Moderna Revenue 2017-2022 | MRNA
Moderna annual/quarterly revenue history and growth rate from 2017 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Moderna revenue for the quarter ending September 30, 2022 was $3.364B, a 32.3% decline year-over-year.
- Moderna revenue for the twelve months ending September 30, 2022 was $21.390B, a 80.8% increase year-over-year.
- Moderna annual revenue for 2021 was $18.471B, a 2200.25% increase from 2020.
- Moderna annual revenue for 2020 was $0.803B, a 1238.33% increase from 2019.
- Moderna annual revenue for 2019 was $0.06B, a 55.58% decline from 2018.
Moderna Annual Revenue
(Millions of US $) |
| 2021 |
$18,471 |
| 2020 |
$803 |
| 2019 |
$60 |
| 2018 |
$135 |
| 2017 |
$206 |
| 2016 |
$108 |
Moderna Quarterly Revenue
(Millions of US $) |
| 2022-09-30 |
$3,364 |
| 2022-06-30 |
$4,749 |
| 2022-03-31 |
$6,066 |
| 2021-12-31 |
$7,211 |
| 2021-09-30 |
$4,969 |
| 2021-06-30 |
$4,354 |
| 2021-03-31 |
$1,937 |
| 2020-12-31 |
$571 |
| 2020-09-30 |
$157 |
| 2020-06-30 |
$67 |
| 2020-03-31 |
$8 |
| 2019-12-31 |
$14 |
| 2019-09-30 |
$17 |
| 2019-06-30 |
$13 |
| 2019-03-31 |
$16 |
| 2018-12-31 |
$35 |
| 2018-09-30 |
$42 |
| 2018-06-30 |
$29 |
| 2018-03-31 |
$29 |
| 2017-12-31 |
|
| 2016-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$65.718B |
$18.471B |
|
Moderna, Inc. is a clinical-stage pharmaceutical company, primarily focused on discovering and developing messenger RNA (mRNA) based therapies. The company's mRNA based COVID-19 vaccine, Spikevax (mRNA-1273), is approved for use in adults in the United States. The vaccine is also authorized for emergency use in several countries as COVID-19 vaccine. The company has also developed booster doses of its COVID-19 vaccine and is developing variant-specific booster candidates.
|
